Quantcast
Last updated on April 20, 2014 at 17:20 EDT

ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product As an Anti-HIV Topical Microbicide

July 29, 2008

FREDERICK, Md., July 29 /PRNewswire/ — ImQuest BioSciences announced today the successful acquisition of funding from the National Institute of Allergy and Infectious Disease (NIAID/NIH) to support the development of pyrimidinedione inhibitors as topical microbicides to prevent the sexual transmission of HIV. The two year Small Business Innovative Research (SBIR) grant provides funding for the continued development of the dual-acting pyrimidinedione molecules which effectively inhibit two critical steps in the HIV replication pathway important for a microbicide. The research to be performed will enable ImQuest scientist’s to comparatively evaluate their most potent lead preventative agents and define the most potent microbicide candidate for advanced preclinical and clinical development.

ImQuest’s Executive Vice President and Chief Scientific Officer, Dr. Robert W. Buckheit, Jr. is the Principal Investigator of the project and leads ImQuest’s efforts to develop microbicide and therapeutic products for treatment and prevention of HIV infection. “Women now account for over 50% of the cases of individuals living with AIDS and the successful development of a microbicide is essential for providing them with an effective means to protect themselves from infection,” explained Dr. Buckheit. “In the absence of an effective vaccine, topical microbicides represent the best means to prevent new HIV infections throughout the world.”

As a component of the grant, ImQuest scientists will work in collaboration with Dr. Patrick Kiser of The University of Utah to develop an optimal formulated gel product which can be used by women to prevent the sexual transmission of HIV. ImQuest plans to file an IND to initiate human clinical microbicide trials with their lead microbicide candidate in 2009.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in early stage drug development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective therapeutic and microbicide development services to the biotechnology and pharmaceutical industry.

   For further information regarding this press release please contact:   Robert W. Buckheit, Jr., Ph.D.   Executive Vice President and Chief Scientific Officer   ImQuest Life Sciences, Inc.   301-696-0274   rbuckheit@imquest.com  

ImQuest BioSciences

CONTACT: Robert W. Buckheit, Jr., Ph.D., Executive Vice President andChief Scientific Officer of ImQuest Life Sciences, Inc., +1-301-696-0274,rbuckheit@imquest.com

Web site: http://www.imquest.com/